The clinical behavior of systemic mastocytosis (SM) is strongly associated with activating mutations in KIT (D816V in >80% of cases), with the severity of the phenotype influenced by additional somatic mutations, for example, in SRSF2, ASXL1, or RUNX1. Complex molecular profiles are frequently associated with the presence of an associated hematologic neoplasm (AHN) and an unfavorable clinical outcome. However, little is known about the incidence and prognostic impact of cytogenetic aberrations. We analyzed cytogenetic and molecular characteristics of 109 patients (KIT D816V1, n 5 102, 94%) with indolent (ISM, n 5 26) and advanced SM (n 5 83) with (n 5 73, 88%) or without AHN. An aberrant karyotype was identified in SM-AHN (16/73, 22%) patients only. In patients with an aberrant karyotype, additional somatic mutations were identified in 12/16 (75%) patients. Seven of 10 (70%) patients with a poor-risk karyotype, for example, monosomy 7 or complex karyotype, and 1/6 (17%) patients with a good-risk karyotype progressed to secondary acute myeloid leukemia (n 5 7) or mast cell leukemia (n 5 1) within a median of 40 months (range 2-190, P 5 .04). In advanced SM, the median overall survival (OS) of poor-risk karyotype patients was significantly shorter than in good-risk/normal karyotype patients (4 vs 39 months; hazard ratio 11.7, 95% CI 5.0-27.3; P < .0001). Additionally, the shortened OS in patients with poor-risk karyotype was independent from the mutation status. In summary, a poor-risk karyotype is an independent prognostic variable in advanced SM. Cytogenetic and molecular
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analyses should be routinely performed in all patients with advanced SM 6 AHN because these investigations greatly support prognostication and treatment decisions. Somatic gain-of-function point mutations within the receptor tyrosine kinase gene KIT, usually D816V, are detectable in 80%-90%
of all SM patients, 5, 6 whereas in advanced SM additional somatic mutations, for example, in SRSF2, ASXL1, and/or RUNX1 (S/A/R pos ), are coexisting with KIT D816V and increase its oncogenic potential.
As a consequence, a complex mutational profile has a significant impact on phenotype, response to treatment, and prognosis. Tables 1 and 2 .
The study followed the tenets of the Declaration of Helsinki and was approved by the ethics committee of the Medical Faculty Mannheim at Heidelberg University, Germany. All patients are registered within the "German Registry on Disorders of Eosinophils and Mast Cells" and gave written informed consent.
| Somatic mutation analyses
For quantitative assessment of KIT D816V expressed allele burden (EAB) of peripheral blood (PB, n 5 102) samples, we used allele-specific quantitative real-time PCR (qPCR) analyses as previously described. 
| RE S U L TS

| Evaluation of patient characteristics
Relevant SM-associated disease characteristics of patients with advanced SM are shown in Table 2 . Elevated laboratory parameters were detected on the serum tryptase level (median 225 lg/L), leukocytes (median 12.3 3 10
The median BM MC infiltration, determined by BM immunohistochemistry, was 32% (range 3-95). The median hemoglobin level was 10.5 g/ dL. The median KIT D816V AB in PB was 23% (range 0.9-100). Overall, there were no significant differences in laboratory characteristics of patients with a normal versus aberrant karyotype except for monocytosis ( Table 2) . 
20 (77) 6 (23) 20 (77) 6 (23) Advanced SM (%) 83 (76) 67 (72) 16 (100) ASM, n (%) 3 (4) 3 (5) - (75) 50 (75) 12 (75) MCL-AHN, n (%) 10 (12) 7 (10) 4 (25) AHN subtype n 5 72 n 5 57 n 5 16 CMML, n (%) 26 (36) 25 (44) 1 (6) MDS/MPNu, n (%) 17 (24) 16 (28) 1 (6) MDS, n (%) 8 (11) 3 (5) 5 (31) MPN-eo, n (%) 7 (10) 7 (12) 1 (6) AML, n (%) 9 (13) 1 (2) 8 (50) MF, n (%) 3 (4) 3 (5) -
ASXL1, n (%) 17 (13) 14 (13) 3 (14) RUNX1, n (%) 11 (8) 8 (7) 3 (14) JAK2, n (%) 13 (10) 12 (11) 1 (5) CBL, n (%) 10 (7)
Abbreviations: AHN, associated hematologic disease; AML, acute myeloid leukemia; ASM, aggressive systemic mastocytosis; CLL, chronic lymphocytic leukemia; CMML, chronic myelomonocytic leukemia; ISM/SSM, indolent/smoldering systemic mastocytosis; MCL, mast cell leukemia; MDS, myelodysplastic syndrome; MDS/MPNu, myelodysplastic/myeloproliferative neoplasm unclassified; MF, myelofibrosis; MPN-eo, myeloproliferative neoplasm with eosinophilia; PV, polycythemia vera; SM, systemic mastocytosis.
| Distribution of cytogenetic and molecular aberrations
Clinical and molecular characteristics of the 109 SM patients are shown
in Table 1 and Figure 1 . Overall, 104/109 (95%) patients had a mutation in KIT (D816V, n 5 102 [94%], D816H, n 5 2). An aberrant karyotype was present in 16 patients; all these patients had advanced SM (SM-AHN, n 5 12; MCL-AHN, n 5 4).
Overall, 62/75 (83%) KIT D816-mutated advanced SM patients had at least one additional somatic mutation. The most frequently affected genes were TET2 (n 5 31, 40%), SRSF2 (n 5 28, 36%), ASXL1 (n 5 18, 23%), RUNX1 (n 5 11, 13%) JAK2 (n 5 11, 13%), CBL (n 5 9, 12%), and K/NRAS (n 5 9, 12%). Less frequently affected genes (<10%) were IDH1/2, EZH2, U2AF1, ETNK1, NPM1, SF3B1, SETBP1, and DNMT3A. Two or more additional somatic mutations were detected in 52% of patients. In patients with an aberrant karyotype, at least one additional mutation was identified in 12/16 (75%) patients. poor-risk karyotype: HR 16.8, 95% CI 6.6-42.9, P < .0001). Significant differences regarding OS were observed when comparing the following 3 groups: good-risk karyotype 1 S/A/R neg (n 5 34) versus good-risk 
| D I SCUSSION
There is only little information available on the incidence and impact of cytogenetic aberrations on disease phenotype and progression in SM and its various subtypes. In our series of patients who were primarily referred to our hematology center with a previous diagnosis of SM, but were subsequently unselected, 15% of all patients, 19%
with advanced SM, and 22% of patients with SM-AHN had an aberrant karyotype. The presence of an aberrant karyotype was strongly associated with advanced SM (100%) and with the presence of an AHN (100%), which is in accordance with other previous smaller studies reporting cytogenetic aberrations in SM-AHN 16, 22 and/or MCL. 23, 24 As additional mutations were already present before the detection of the poor-risk karyotype, we could show that a poorrisk karyotype affects the OS independently of mutational status.
We also found that (a) chromosomal aberrations most frequently were deletions [del(5q), del(1q), del(12q)], followed by trisomies [18] , monosomies [27] , and complex karyotypes (Table 3 and 
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